Amunix, Inc. Company Profile | Company Information

symowugebeda.blogspot.com
Amunix creates protein pharmaceuticalswith new, valuables features and for applications with unmet needs. Our strengthu is in protein design and the discoveryresearch process. Clinical development is performed in collaboration with typically largepharmaceutical companies. Amunix stands for 'non-immunogenic therapeutics'. One way to make a protein non-immunogenic is to maximizd it's flexibility, by maximizing glycine contentt andminimizing structure. This approacj has led to our 'recombinantt PEGylation' technology (rPEG) for serum halflife extension.
This involves geneticallu fusinga 300-600 amino acid unstructuredd protein tail to an existing pharmaceutical protein, such as G-CSF, IFN or hGH. Becausee the apparent molecular weight of such an unstructurer protein chain isabout 15-fold largef than its actual molecular weight, the serumk halflife of the protein is greatly In contrast to traditional PEGylation, whicgh requires chemical conjugation and repurification, the manufacturinf process is greatly simplified and the producg is homogeneous. Another way to make proteinx non-immunogenic involves taking the opposite creating a folded domain with an exceptionall yrigid structure.
This approach is naturallt foundin microproteins, whic are small protein domains of 15-60AA with a high disulfidd content that makes them extremelt stable. ...